Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality

Journal of the American Society of Nephrology

Volumn 22, Issue 5, 2011, Pages 956-966

  Wolf, Myles ^a   Molnar, Miklos Z ^b,c   Amaral, Ansel P ^a   Czira, Maria E ^b   Rudas, Anna ^b   Ujszaszi, Akos ^b   Kiss, Istvan ^d   Rosivall, Laszlo ^b   Kosa, Janos ^b   Lakatos, Peter ^b   Kovesdy, Csaba P ^e,f   Mucsi, Istvan ^b,g  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d Szent Imre Hospital   (Hungary)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SURGICAL MORTALITY;

EID: 79955603792     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010080894     Document Type: Article

References (46)

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730, 1999
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346: 580-590, 2002 (Pubitemid 34438820)
3. Howard RJ, Patton PR, Reed AI, Hemming AW, Van der Werf WJ, Pfaff WW, Srinivas TR, Scornik JC: The changing causes of graft loss and death after kidney transplantation. Transplantation 73: 1923-1928, 2002
4. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
5. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
6. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
7. Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE: Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24: 3125-3131, 2009
8. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551, 2009
9. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 152: 640-648, 2010
10. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25: 3983-3989, 2010
11. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P: Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120: 1784-1792, 2009
12. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007 (Pubitemid 46762749)
13. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005 (Pubitemid 41725150)
14. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73: 1296-1302, 2008 (Pubitemid 351693159)
15. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Juppner H, Wolf M: Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int 70: 1486-1494, 2006
16. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y: Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7: 1193-1200, 2007 (Pubitemid 46643105)
17. Evenepoel P, Meijers BK, de Jonge H, Naesens M, Bammens B, Claes K, Kuypers D, Vanrenterghem Y: Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 3: 1829-1836, 2008
18. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005 (Pubitemid 41716454)
19. United States Renal Data System: Annual data report. Transplantation. Available at http://www.usrds.org/2009/pdf/V2-07-09.PDF. Accessed October 20, 2010
20. Wolf M: Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427-1435, 2010
21. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006 (Pubitemid 44949607)
22. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005 (Pubitemid 40464013)
23. Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor- 23 and early decrements in kidney function: The Heart and Soul Study. Nephrol Dial Transplant 25:
24. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling- Perry K, Wolf M, Salusky IB, Juppner H: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95: 578-585, 2010
25. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003 (Pubitemid 37449564)
26. Schaeffner ES, Fodinger M, Kramar R, Sunder-Plassmann G, Winkelmayer WC: Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int 20: 247-255, 2007
27. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP: Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 87: 1040-1044, 2009
28. Am H, Fidler ME, Myslak M, Morales P, Kremers WK, Larson TS, Stegall MD, Cosio FG: Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 7: 2748-2756, 2007 (Pubitemid 350045780)
29. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007
30. Ahmadpoor P, Ilkhanizadeh B, Ghasemmahdi L, Makhdoomi K, Ghafari A: Effect of active vitamin D on expression of co-stimulatory molecules and HLA-DR in renal transplant recipients. Exp Clin Transplant 7: 99-103, 2009
31. Amuchastegui S, Daniel KC, Adorini L: Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation 80: 81-87, 2005 (Pubitemid 40980899)
32. Mathieu C, Jafari M: Immunomodulation by 1,25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clin Nephrol 66: 275-283, 2006 (Pubitemid 44541215)
33. Isakova T, Gutierrez OM, Wolf M: A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 76: 705-716, 2009
34. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C: Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288: 3014-3018, 2002 (Pubitemid 35471163)
35. Juppner H, Wolf M, Salusky IB: FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res 25: 2091-2097, 2010
36. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG, Koch KM: Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 96: 2809-2819, 1995
37. Kriz W, Hahnel B, Rosener S, Elger M: Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 48: 1435-1450, 1995
38. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010
39. Jassal SV, Schaubel DE, Fenton SS: Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices. Am J Kidney Dis 46: 136-142, 2005 (Pubitemid 40848442)
40. K/DOQI Clinical Practice Guidelines for Evaluation of Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 39: S46-S76, 2002
41. Fine J, Gray R: A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 94: 496-509, 1999
42. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 95: 1741-1748, 2010
43. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
44. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005 (Pubitemid 41710323)
45. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M: Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20: 388-396, 2009
46. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G: Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21: 1853-1861, 2010